PRESS-RELEASE filed Jul 27, 2026 at 01:00 ET
argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP since positive Phase 1b vitiligo data. The deal adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, fitting argenx's strategy to expand its immunology pipeline beyond FcRn blockade. The acquisition is fully funded from cash on hand and expected to close in Q3 2026, with no financing condition, a disciplined bolt-on that broadens argenx's T-cell/NK-cell targeting capability without diluting shareholders.